» Articles » PMID: 34298840

Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Jul 24
PMID 34298840
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Papillary thyroid cancer (PTC) and poorly differentiated thyroid cancer (PDTC) are treated with radioiodine to reduce recurrence and to treat the spread of disease. Adequate iodine accumulation in cancer tissue, iodine avidity, is important for treatment effect. This study investigated which clinical and histological tumour characteristics correlate with avidity. To quantify avidity in cancer tissue, tracer amounts of iodine-131 were given to 45 patients with cytologically confirmed thyroid cancer. At pathology grossing, representative samples of tumour and lymph nodes were taken and subjected to radioactivity quantification ex vivo to determine avidity. Afterwards, samples underwent extended pathology work-up and analysis. We found that tumoural Tg expression and Ki-67 index were correlated with avidity, whereas tumour size and pT stage were not. The histological variant of thyroid cancer was also correlated with iodine avidity. Variants associated with worse clinical prognoses displayed lower avidity than variants with better prognoses. This work provides new information on which tumours have low iodine avidity. Lower avidity in aggressive histological PTC variants may explain their overall poorer prognoses. Our findings also suggest that radioiodine dosage could be adapted to Tg expression, Ki-67 index or histological variant instead of pT stage, potentially improving the efficacy of radioiodine therapy.

Citing Articles

Comprehensive Gene Expression Analysis in Papillary Thyroid Carcinoma Reveals a Transcriptional Profile Associated with Reduced Radioiodine Avidity.

Condello V, Marchettini C, Ihre-Lundgren C, Nilsson J, Juhlin C Endocr Pathol. 2025; 36(1):4.

PMID: 39982585 PMC: 11845550. DOI: 10.1007/s12022-025-09849-0.


Role of [F]FDG PET/CT in the management of follicular cell-derived thyroid carcinoma.

Zajkowska K, Cegla P, Dedecjus M Cancer Imaging. 2024; 24(1):147.

PMID: 39468677 PMC: 11514821. DOI: 10.1186/s40644-024-00791-8.


Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making.

Chatterjee S, Mair M, Shaha A, Paleri V, Sawhney S, Mishra A Endocrine. 2024; 85(2):509-519.

PMID: 38504051 DOI: 10.1007/s12020-024-03771-x.


Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.

Coca-Pelaz A, Rodrigo J, Agaimy A, Williams M, Saba N, Nuyts S Virchows Arch. 2024; 484(5):733-742.

PMID: 38400843 DOI: 10.1007/s00428-024-03752-5.


Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up.

Nilsson J, Siikanen J, Condello V, Jatta K, Saini R, Hedman C Eur Thyroid J. 2023; 12(4).

PMID: 37352166 PMC: 10388652. DOI: 10.1530/ETJ-23-0099.


References
1.
Rivera M, Ghossein R, Schoder H, Gomez D, Larson S, Tuttle R . Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008; 113(1):48-56. DOI: 10.1002/cncr.23515. View

2.
Walczyk A, Kopczynski J, Gasior-Perczak D, Palyga I, Kowalik A, Chrapek M . Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients. PLoS One. 2020; 15(2):e0229264. PMC: 7039429. DOI: 10.1371/journal.pone.0229264. View

3.
Ambrosi F, Righi A, Ricci C, Erickson L, Lloyd R, Asioli S . Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review. Endocr Pathol. 2017; 28(4):293-301. DOI: 10.1007/s12022-017-9502-7. View

4.
Ringel M, Anderson J, Souza S, Burch H, Tambascia M, Shriver C . Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol. 2001; 14(4):289-96. DOI: 10.1038/modpathol.3880305. View

5.
Dunn L, Sherman E, Baxi S, Tchekmedyian V, Grewal R, Larson S . Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. J Clin Endocrinol Metab. 2018; 104(5):1417-1428. PMC: 6435099. DOI: 10.1210/jc.2018-01478. View